Fig. 2.
PLX4720 extends survival and reverses cachexia in orthotopic mice with human ATC. A, Mouse weight over time. B, Untreated mice developed weight loss, piloerection, and cachexia by 28 d. Vehicle-treated mice progressed to severe cachexia, whereas PLX4720-treated mice had reversal of weight loss, cachexia, and piloerection over the 3-wk course of therapy. *, P < 0.05.